"Cancer in children isn’t profitable enough for the pharmaceutical industry"

CRIG
23 November 2020 |

A new method to diagnose cancer more rapidly: pediatric oncologist Bram De Wilde is on the verge of a potential breakthrough with his research. And this despite the pharmaceutical industry: "the patient pool is too small for pharmaceutical companies; they do not invest in it." So, financial backing has to come from somewhere else.

De Wilde is one of many researchers linked to the CRIG, the Cancer Research Institute Ghent. The Ghent research center wants to stimulate and accelerate multidisciplinary cancer research: by sharing knowledge and technology, making collaboration between researchers possible, and by making financial backing available. This is support that primarily comes from donations. As a pediatric oncologist, De Wilde is confronted with the need for donations every day.

Why is there so little money for childhood cancer research?

"Fortunately, cancer is not very prevalent in children: it constitutes only 1% of all types of cancer, but this makes it too small a group for the pharmaceutical industry to invest in; it is not lucrative enough. There is a substantial need for better treatments, as it can have dire consequences for the little patient and their families. We want them to be less subjected to pain during treatment, to suffer less organ damage, and be less impacted by psychological consequences. Things are particularly difficult during that uncertain period when the diagnosis is not yet clear. It is thanks to donations to the CRIG that these unprofitable initiatives can still benefit from financial backing."

What research did you conduct with support from the CRIG?

"We have developed a new technique that defines, with greater certainty, what type of cancer someone has in just a few days’ time and what treatment needs to be followed. Up until today, this usually required a lot more time."

How does this new technique work?

"Instead of taking a tissue sample, the detection of a tumor is done through a blood sample or another liquid biopsy, like urine. The ground-breaking aspect is the speed: within an hour of taking the blood, we can start with the tumor analysis. That is very fast. Another innovation is that we also immediately know exactly what tumor it is. With a tissue biopsy, you are often dealing with metastases and it can be a bit of guesswork to identify the primary tumor. Furthermore, getting a tissue sample is often delicate or even impossible, for instance when it relates to kidneys or the brain. In those instances, we would sometimes have to start treatment without being 100% sure of the diagnosis."

What part did the CRIG play in this?

"Thanks to financial backing from the CRIG, we were able to prove that the test works from a technical standpoint. In other words, we can establish a diagnosis with much more certainty. The first results show that the technique delivers high-quality results. It is important that we now secure the extra funding needed to develop the project further."

Are donations still needed for cancer research today?

"Financing for this type of research by Kom op tegen Kaner or the Fonds voor Wetenschappelijk Onderzoek, for instance, is only awarded if you can show that your project will deliver results. New or early-stage researchers and innovative ideas that don’t yet offer proof will not be considered. Without donations, the research would not have come as far as it has done."

Support CRIG

With CRIG, physicians and researchers from Ghent University, UZ Gent and VIB-UGent are committed to jointly address the medical challenges of the future in cancer treatment. The focus is mainly on top research that, in collaboration with the clinic and the industry, can lead to more effective treatments and to longer and better survival.

Read also

Is it easier to live with HIV than with the stigma that surrounds it?

HIV, the virus that causes AIDS, surfaced in the eighties. Long gone are the times when the virus was a sure death sentence. Still, even after all these years the stubborn stigma that surrounds HIV persists. Why is that and what can be done about it?

Laurence Hendrickx en Melissa Ceuterick
view

No more painful mammograms thanks to researchers in Ghent?

Researchers around the world are looking for innovative ways to detect and treat breast cancer. So are experimental oncologist An Hendrix and medical oncologist Hannelore Denys, two top researchers from Ghent.

Hannelore Denys en An Hendrix
view

Can the cause of Parkinson’s be found in our intestines? “More research is required, but that costs money”

There are currently an estimated 35,000 cases of Parkinson’s in our country. This figure increases every year. In fact, it is the fastest growing neurodegenerative illness, yet we know so little about it. Professors Roosmarijn Vandenbroucke and Patrick Santens are looking to gain knowledge of the disease with their research. “But that means that particularly large sums of money are required, and these are often unavailable”, they confirm.

Professor Vandenbroucke en Santens
view

Imke searches for lost voices

Imke Kissel researches unilateral vocal cord paralysis and wants to develop therapies tailored to the needs of patients.

Verloren stemmen
view